April 16, 2018 / 1:49 PM / in a year

Bristol-Myers says cancer drug combo reduces death risk

(Reuters) - Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in previously untreated patients with a type of lung cancer.

The combination demonstrated a higher rate of progression-free survival, compared with chemotherapy in a late-stage trial, the company said.

The results come a week after rival Merck & Co said a trial testing its blockbuster drug Keytruda as a monotherapy in previously untreated lung cancer patients was successful.

Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below